8-K: Indivior PLC Announces Q1 2025 Results; FY 2025 Guidance Reaffirmed

Indivior PLC reports first quarter 2025 results, with total net revenue of $266 million and reaffirms its FY 2025 guidance.

Summary

• Indivior PLC announced its first quarter 2025 results, reporting a total net revenue of $266 million, which is in line with expectations.
• SUBLOCADE net revenue was $176 million, consistent with the FY 2025 guidance of $725 million to $765 million.
• The company is on track to deliver gross annual operating expense savings of over $100 million in FY 2025.
• Net revenue decreased by 6% compared to Q1 2024, primarily due to intensified generic competition for SUBOXONE Film in the U.S. and the discontinuation of PERSERIS.
• SUBLOCADE experienced solid growth in organized health systems (OHS), but net revenue declined modestly due to funding gaps among certain justice system customers.
• The company expects SUBLOCADE growth to resume in the second half of FY 2025 due to increased marketing investments and FDA-approved label changes.
• The FDA approved label changes for SUBLOCADE on February 24, 2025, including a rapid initiation protocol and alternative injection sites.
• The estimated last subject last visit for INDV-2000 is now expected in H1 2026, delayed from the previous estimate of Q4 2025 due to lower enrollment conversion rates.
• Indivior's fourth $100 million share repurchase program was completed on January 31, 2025, with 9,415,726 shares repurchased at a weighted average price of $10.62.
• The company's FY 2025 guidance remains unchanged, with net revenue projected between $955 million and $1,025 million and SUBLOCADE net revenue between $725 million and $765 million.
• U.S. BMAT market grew mid-single digits in volume terms in Q1 2025, and long-term U.S. growth is expected to be sustained in the midto high-single digit percentage range.
• Cash and investments totaled $400 million at the end of Q1 2025, an increase of $53 million compared to the end of 2024.
• Indivior has revised its previously issued financial statements to correct the methodology used to accrue for the company's share of the annual U.S. fee imposed on drug manufacturers (the Branded Fee).

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is on track with some goals and reaffirms guidance, there are revenue declines and study delays.

Positives

• Total net revenue was in line with expectations at $266 million.
• SUBLOCADE net revenue is consistent with FY 2025 guidance, reaching $176 million.
• The company is on track to deliver over $100 million in gross annual operating expense savings in FY 2025.
• FDA approved label changes for SUBLOCADE, improving patient and physician experience.
• U.S. BMAT market is experiencing mid-single digit growth.
• Cash and investments increased by $53 million to $400 million at the end of Q1 2025.
• Share repurchase program completed, returning capital to shareholders.

Negatives

• Total net revenue decreased by 6% compared to Q1 2024.
• SUBLOCADE net revenue declined modestly due to funding gaps among certain justice system customers.
• U.S. SUBOXONE Film net revenue declined due to intensified generic competition.
• Gross margin decreased from 87% in Q1 2024 to 83% in Q1 2025.
• INDV-2000 study completion delayed to H1 2026 due to lower enrollment conversion rates.

Risks

• Intensified generic competition for SUBOXONE Film could further erode market share and revenue.
• Funding gaps among justice system customers may continue to negatively impact SUBLOCADE revenue.
• Delays in clinical trials, such as the INDV-2000 study, could postpone potential future product launches.
• Changes in Medicaid eligibility policy or Federal funding levels could impact revenue.
• Potential impacts from tariffs imposed by the U.S. government or retaliatory tariffs from other countries could affect financial results.
• Failure to achieve market acceptance of OPVEE could impact revenue projections.

Future Outlook

The company's FY 2025 guidance remains unchanged, with net revenue projected between $955 million and $1,025 million and SUBLOCADE net revenue between $725 million and $765 million. Long-term U.S. growth is expected to be sustained in the midto high-single digit percentage range.

Management Comments

• Our first quarter results were in line with our planning assumptions and consistent with our FY 2025 outlook, said Mark Crossley, Chief Executive Officer.
• Net revenue performance was primarily impacted by intensified generic competition for SUBOXONE Film in the U.S. and the discontinuation of PERSERIS in the prior year.
• I believe that our team, under Joe Ciaffonis leadership, will deliver the next chapter of growth and value creation for Indivior.

Industry Context

Indivior operates in the opioid use disorder (OUD) treatment market, which is experiencing growth due to increased awareness and destigmatization efforts. The company faces competition from generic manufacturers of SUBOXONE Film and is focused on expanding the use of SUBLOCADE and OPVEE to address the opioid crisis.

Comparison to Industry Standards

• Indivior's performance can be compared to companies like Alkermes, which also develops and commercializes treatments for addiction.
• The growth in the U.S. BMAT market, which Indivior estimates at mid-single digits, aligns with broader trends in the adoption of medication-assisted treatment for OUD.
• Indivior's focus on long-acting injectable buprenorphine (SUBLOCADE) reflects a trend towards more convenient and adherent treatment options, similar to strategies employed by other pharmaceutical companies in different therapeutic areas.

Management Changes

Stakeholder Impact

• Shareholders: Share repurchase program returns capital, but revenue declines may raise concerns.
• Employees: Streamlining actions and cost reductions may impact job security.
• Patients: FDA-approved label changes for SUBLOCADE improve treatment experience.
• Customers: Intensified generic competition for SUBOXONE Film may lower prices.
• Suppliers: Cost reduction efforts may put pressure on pricing.

Next Steps

• Continue to focus on policy changes to enable broader access to nalmefene opioid rescue treatments and on increasing product trial among targeted users for OPVEE.
• Progress the pipeline of INDV-2000 and INDV-6001 through clinical trials.
• Monitor and manage the impact of generic competition on SUBOXONE Film.
• Increase marketing investments to drive SUBLOCADE growth in the second half of FY 2025.

Key Dates

Keywords

Indivior, SUBLOCADE, SUBOXONE, OPVEE, OUD, Net Revenue, Financial Results, Guidance, Pharmaceuticals, Healthcare